Overactive bladder syndrome: A review and update

IOAN SCARNECIU1*, SORIN LUPU2*, OVIDIU GABRIEL BRATU3, ANDREEA TEODORESCU4*, LAURIAN STEFAN MAXIM1, ADRIAN BRINZA1, ALEXANDRU GEORGIAN LACULICEANU4, RUXANDRA MARIA ROTARU1, AURA-MIHAELA LUPU5 and CAMELIA CORNELIA SCARNECIU4*

1Department of Medical and Surgical Specialities, Faculty of Medicine, ‘Transilvania’ University of Brasov, 500019 Brasov; 2Clinic of Urology, Brasov Emergency Clinical County Hospital, 500326 Brasov; 3Clinical Department 3, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest; 4Department of Fundamental, Prophylactic and Clinical Disciplines, Faculty of Medicine, ‘Transilvania’ University of Brasov, 500019 Brasov; 5Department of Radiology, Brasov CF General Hospital, 500097 Brasov, Romania

Received August 6, 2021; Accepted September 7, 2021

DOI: 10.3892/etm.2021.10879

Correspondence to: Dr Sorin Lupu, Clinic of Urology, Brasov Emergency Clinical County Hospital, 25 Calea Bucuresti Street, 500326 Brasov, Romania
E-mail: so_lupu@yahoo.com

*Contributed equally

Abstract. Overactive bladder syndrome is a chronic, disabling condition with physical, psychological and social consequences that significantly affects the quality of life of millions of patients worldwide. The economic impact of this disorder is crucial. Overactive bladder syndrome is a little-known condition, with different manifestations from patient to patient, which causes a great deal of frustration to the medical staff involved. The patient requires a clear explanation and the full support of the attending physician. It is extremely important to establish a correct diagnosis and an effective individualized treatment. The collaboration and understanding of these patients are extremely important aspects. Improving the quality of life in these patients is the main purpose in managing this condition. There are several treatment modalities that may be used progressively, with favorable albeit inconsistent results. This condition remains extremely challenging for specialists and, unfortunately, always one of maximum interest.

Contents

1. Introduction
2. Risk factors
3. Pathophysiology of OAB syndrome
4. Evaluation of patients with OAB syndrome
5. Treatment
6. Discussion of the treatment algorithm
7. Conclusions

1. Introduction

Overactive bladder (OAB) syndrome is a chronic condition that affects both men and women, accompanied by a marked impairment of the patients’ quality of life (1,2). Although it is more common in the population over the 4th decade, it can affect both children and young individuals (3). A study published in 2011 with a sample size of 10,000 individuals from Europe found that approximately 36% of men and 43% of women over the age of 40 had symptoms of OAB (4). It has been established that the severity of symptoms has a direct correlation with the patient’s age: more severe symptoms at an older age (5,6). The National Overactive Bladder Evaluation Program (NOBLE) also showed a prevalence of over 33 million individuals with OAB in the US population (7).

The term OAB was first used in 1988 by The International Continence Society (ICS) Committee on Standardization of Terminology, referring to detrusor hyperactivity shown in urodynamic tests (8). Over the years, the definition of OAB has undergone many changes. The most accurate and accepted worldwide definition at this moment is that of the International Consultation on Incontinence Research Society (ICI-RS) from 2014: ‘overactive bladder syndrome is characterized by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia, if there is no proven infection or other obvious pathology’ (9).

Thus, the symptoms that characterize OAB are urgency, frequency, nocturia and urgency incontinence. Many patients have combinations of these symptoms, with varying preponderance (1,6). The key element that characterizes OAB is urgency which together with nocturia and urgency urinary incontinence, are considered the most irksome symptoms (1,10-13). It is
estimated that urgency incontinence is more common in women, and urgency and frequency are more common in men (14).

The symptom has a significant impact on the quality of life of these patients leading to frequent sleep disorders, anxiety and depression, as well as reduction of physical activity and social interactions, reduction of sexual activity and marital satisfaction (15-18). Due to sleep disorders, it has been shown that patients with OAB have a much higher risk of fractures or fall-related injuries (6,13,15).

The economic impact of OAB is crucial. As an example, a study conducted in 2005 in the USA showed total costs of over 12 billion USD per year for patients with OAB. To these are added indirect costs such as temporary loss of work capacity (15,19-21). OAB is a captivating and still unknown subject in many aspects, especially in terms of the possible risk factors, pathological mechanisms involved and effective treatment, causing marked frustration in physicians and conflicting feelings in patients (1,18,22).

For the literature review a database search was performed in MEDLINE and ScienceDirect with the following key words: ‘overactive bladder’, ‘quality of life’, ‘antimuscarinic drugs’, ‘β3-agonists’, ‘intravesical botulinum toxin A’. The time frame in MEDLINE and ScienceDirect with the following key words: ‘overactive bladder’, ‘quality of life’, ‘antimuscarinic drugs’, ‘β3-agonists’, ‘intravesical botulinum toxin A’. The time frame in particular to recurrent urinary tract infections (UTIs) that occur through chronic urinary retention] (22,39).

2. Risk factors

A well-known risk factor is age (1,14,15). In women, due to the postmenopausal status, by reducing the level of estrogen, the prevalence of symptoms is higher, as demonstrated by numerous studies (15,22,23). Genital prolapse is also associated with an increased risk of OAB (consequently, treatment of prolapse leading to relief of OAB symptoms) (24). However, there are studies that have not clearly demonstrated this (24). Stress urinary incontinence surgery may also cause OAB (15). In men, the data related to possible hormonal factors involved in the occurrence of OAB, are extremely low and contradictory (22). Other possible risk factors involved include, i) BMI >30 kg/m²; there are studies that have shown a clear link between OAB and obesity in both sexes, the possible explanations being related to mechanical factors, and to inflammatory syndrome or oxidative stress (15,22,25,26), ii) Affective disorders: OAB can cause many mental disorders such as anxiety or depression; however, there are studies that show that the presence of these disorders itself can increase the risk of OAB; corticotrophin-releasing factor (CRF) being the possible common factor (22,27). iii) Functional gastrointestinal disorders: the most common is irritable bowel syndrome, present in approximately 33.3% of OAB cases (22,28), iv) Autonomic nervous system dysfunction (autonomic balance dysfunction) (22), v) Ethnicity is another potential risk factor, with studies showing a higher prevalence of OAB in African-American and Hispanic patients (29). vi) Sleep apnea, urinary microbiota, smoking, increased coffee consumption, artificial sweeteners, alcohol, spices and sour drinks are other possible involved factors (2,15,26,30).

3. Pathophysiology of OAB syndrome

According to the ICS, detrusor overactivity (DO) is defined as: ‘a urodynamic observation characterized by involuntary detrusor contractions during the filling phase which may be spontaneous or provoked’ (31). The etiology of OAB is not well known, but all theories are related to the term ‘detrusor overactivity’, suggesting that the sensory mechanisms of the bladder are affected in these situations, which leads to the creation of an ‘urgency’ in emptying the bladder at smaller or much smaller quantities than under normal conditions. This is because the detrusor (bladder muscle) is very strongly innervated, and the function of the bladder is ensured by a complex mechanism of interactions between the central and peripheral nervous system (1,32).

The motor component of the bladder is served by the parasympathetic nervous system (S2, S3 and S4) andcoordinates the intensity of detrusor contractions. The sympathetic component comes from the hypogastric nerve, acts on beta receptors and is responsible for relaxing the detrusor (33). However, not all patients with OAB also have DO, which is proven in only approximately 50% of cases (6,13,22). Various theories have been posited to identify the factors involved. These theories include, i) the myogenic theory whereby urgency is caused by a problem with the detrusor. The detrusor is much more sensitive to cholinergic stimulation, as demonstrated by Brading (34). Other authors have demonstrated other detrusor dysfunctions that contribute to uninhibited detrusor contractions (22,35). ii) The urotheliogenic theory where urgency is determined by a bladder urothelium/suburothelium problem (1,22,36). iii) The supraspinal theory: urgency has its origin in the brain and brainstem. With age, deterioration in certain segments of the white matter is possible, leading to urinary disorders (38). iv) Detrusor underactivity: secondary to urothelial or suburothelial dysfunction or from detrusor muscle dysfunction, accompanied by detrusor underactivity appears urgency, which has been found in many studies [due in particular to recurrent urinary tract infections (UTIs) that occur through chronic urinary retention] (22,39).

4. Evaluation of patients with OAB syndrome

A detailed history is extremely important and can clearly highlight possible risk factors for OAB. Aspects related to pre-existing conditions or surgery (especially urinary tract, but also systemic disorders, important for differential diagnosis), eating habits, medication that interferes with urinary function are crucial. History should be focused especially on voiding and storage lower urinary tract symptoms, the severity of symptoms and their impact on quality of life (1,6,13,15,18,22).

A focused clinical examination is imperative, as it can highlight risk factors and pre-existing conditions. It should include abdominal examination, digital rectal examination of the prostate in males and vaginal examination in women (important to highlight hormonal status, presence of prolapse and cough testing for the presence of leakage) (1,6,15,18,22). A residual postvoid should also be performed using ultrasound or a straight catheter, especially in groups at risk of urinary retention (6,18).

Symptom questionnaires should be used especially to highlight the impact of the condition on quality of life and to determine whether or not the patient should undergo treatment.
There are numerous validated questionnaires, useful in highlighting the progression of treatment, but not currently widely used (6,15,18).

The use of voiding diaries is recommended as it shows the patient's daily urination habits. It is a simple tool, easy to apply, which can highlight urinary volume, frequency, pattern of voiding, incontinence episodes and can assess the severity of symptoms (sometimes underestimated by the patient or overestimated by the doctor). It is estimated that three days of a bladder diary provides very important information about the patient. A bladder diary can also be useful to evaluate the response to treatment (1,6,15,18,40).

Urinalysis and urine culture are recommended for all patients in order to rule out other associated pathologies that may cause OAB-type symptoms (especially UTI and hematuria) (1,15,18). Blood tests can provide additional information including levels of creatinine and glycosylated hemoglobin (HbA1C) (1).

In more complicated situations or in patients refractory to treatment, other additional tests may be performed such as cystoscopy (in case of recurrent hematuria or UTI), urodynamic evaluation (especially in situations where there is a history of neurological symptoms or concomitant voiding dysfunction), upper genitourinary tract imaging (in case of hematuria or to exclude other concomitant diseases) (1,6,15,18).

5. Treatment

Non-pharmacological treatment (first-line treatment). Its main role is to educate the patient in order to understand what OAB is and to assist the patient in identifying symptom management strategies. The patient must understand, from the beginning, that they are to undergo treatment over a lengthy period of time, that they must remain motivated and, especially tolerant (1,6,13-15,18).

First-line treatment is considered to be behavioral therapy, especially since it does not involve risks and its effectiveness is proven in many cases (6,13). The patient is advised to make changes in lifestyle: to lose weight, reduce fluid intake (six to eight glasses of water per day, avoiding fluid intake 2 h before bedtime), to give up coffee, spices, sour drinks and alcohol, smoking cessation, bowel regulation (avoid constipation), to increase the level of physical activity and to improve overall health. All these have been confirmed to have beneficial results (1,6,13-15,18,41,42).

Bladder training is part of the arsenal of non-pharmacological treatment, with promising results (1,6,13,15,43). It consists of urinating at regular intervals, starting with urination before bedtime), to give up coffee, spices, sour drinks and alcohol, smoking cessation, bowel regulation (avoid constipation), to increase the level of physical activity and to improve overall health. All these have been confirmed to have beneficial results (1,6,13-15,18,41,42).

Bladder training is part of the arsenal of non-pharmacological treatment, with promising results (1,6,13,15,43). It consists of urinating at regular intervals, starting with urination before bedtime), to give up coffee, spices, sour drinks and alcohol, smoking cessation, bowel regulation (avoid constipation), to increase the level of physical activity and to improve overall health. All these have been confirmed to have beneficial results (1,6,13-15,18,41,42).

Bladder training is part of the arsenal of non-pharmacological treatment, with promising results (1,6,13,15,43). It consists of urinating at regular intervals, starting with urination before bedtime), to give up coffee, spices, sour drinks and alcohol, smoking cessation, bowel regulation (avoid constipation), to increase the level of physical activity and to improve overall health. All these have been confirmed to have beneficial results (1,6,13-15,18,41,42).

Bladder training is part of the arsenal of non-pharmacological treatment, with promising results (1,6,13,15,43). It consists of urinating at regular intervals, starting with urination before bedtime), to give up coffee, spices, sour drinks and alcohol, smoking cessation, bowel regulation (avoid constipation), to increase the level of physical activity and to improve overall health. All these have been confirmed to have beneficial results (1,6,13-15,18,41,42).

Thus, it is opportune to commence with small doses, on a plan as flexible as possible, and to evaluate the patient as closely as possible, at 1-3 months, in order to manage the case as correctly as possible and, especially, the patient's ability to cope with the side effects. This is crucial as the rate of side effects increases with increasing doses (1,6,13,14,54). Contraindications to antimuscarinic medication are: patients with narrow-angle glaucoma (unless approved by the ophthalmologist treating), myasthenia gravis, severe ulcerative colitis, toxic megacolon,
urinary retention or intestinal obstruction. Caution should be accorded when prescribed to elderly patients or those who already have cognitive impairment, or if the patient is using other medications with anti-cholinergic properties, although studies are contradictory in this regard. Cognitive side effects are cumulative and increase with length of exposure, so antimuscarinics should be used with caution in elderly patients. In other words, each case must be managed carefully and individually, sometimes in collaboration with other clinicians in other specialties, to weigh the ratio between risks and benefits (1,6,13,15,18).

The second type of drug that is used is β3-agonists. Of the three β adrenergic receptors present in the bladder, findings have shown that β3 is predominant and responsible for detrusor relaxation during the filling phase (55,56). Mirabegron is the only licensed β3-agonist available since 2013, and studies have shown favorable results on OAB symptoms. Additionally, this agonist is well tolerated. Mirabegron is considered a second-line therapy. The effectiveness is comparable to that of antimuscarinics, but with decreased side effects, especially those related to the incidence of dry mouth (1,6,15,18,57).

The side effect profile is different in β3-agonists because the mechanism of action is different. β3 adrenergic receptors are also present in vascular and cardiac tissue, with studies showing some changes in heart rate and increases in blood pressure, albeit not notable ones. Other possible side effects are nasopharyngitis and UTI, which are less common (13,15,58).

The use of mirabegron as an alternative to antimuscarinic therapy is recommended especially in patients who do not respond to first-line treatment and in those who cannot tolerate side effects (6,13,15,18). There was a much greater adherence to mirabegron treatment when compared to antimuscarinics (13,59). Additionally, in patient refractory to monotherapy, antimuscarinics may be combined with mirabegron, the results being superior to monotherapy (6,13,15,18,60). In elderly patients, existing data have shown that mirabegron is safe (13).

**The management of refractory patients (third-line therapy).** When patients do not respond to anticholinergic medication or to β3-agonists, they are considered refractory. This category also includes patients who have used at least 2 types of anticholinergics or combination treatment without results, or those who do not tolerate side effects or have contraindications for first-line or second-line therapy. In such cases resorting to third-line therapy is inevitable: temporary chemical denervation of the bladder detrusor muscle, peripheral tibial nerve stimulation (PTNS) or neuromodulation (1,6,14,15).

**Temporary chemical denervation of the bladder detrusor muscle with intravesical botulinum toxin A (OBTA).** OBTA is derived from *Clostridium botulinum* and selectively blocks presynaptic release of acetylcholine from nerve endings. This results in reduced contractility and a degree of muscle atrophy at the injection site (a temporary degree of paralysis). The result is not permanent due to the formation of new functional synapses. Another mode of action appears to be directly in the urothelium by inhibiting the release of neurotransmitters at this level, thus acting on the sensory system (1,15,18,61). OBTA is administered intravesically, by injection into certain areas of the bladder, using a cystoscope. The injection is made in 20 places at the level of the posterior wall of the bladder, above the trigone, to avoid extreme paralysis and significant urinary retention. The optimal dose is considered to be 100 units (6,13,15,18). Findings have shown that higher doses are more effective, but reported side effects have been much more common (18,62). Higher doses may be used in selected cases, but patients should be informed of the much higher likelihood of urinary retention (15).

Local or systemic side effects are reduced at the standard dose of 100 units, but the main problem is related to increased PVR (residual volume). As a result the patient must be compliant and able to perform clean intermittent self-catheterization. It is reported that urinary difficulties appear in 4–45% of patients (6,13,15,18,55,63). Other side effects of the injection are UTIs (13–44%), hematuria, dysuria, rash, transient flu-like illness or generalized muscle weakness (14,18,64). Favorable results of OBTA treatment, with marked improvement of symptoms, urodynamic parameters and significant improvement of quality of life have been reported. The duration of the favorable effect is estimated to be 6–9 months, after which a new administration of OBTA may be necessary (1,13,15,18,65). The most common causes of withdrawal are ineffective treatment (13%) and problems with secondary urinary disorders (11%) (1). Intravesical OBTA was approved by FDA in 2013 for the treatment of idiopathic OAB.

Posterior tibial nerve stimulation (PTNS) was first described in 1983 and is a minimally invasive procedure with favorable results and low risks. It consists of intermittent stimulation applied to the posterior tibial nerve using a small needle electrode (34-G) inserted just above the medial aspect of the ankle (P-PTNS). The success rate is estimated at 60–80% (1,6,13,14,66–68). The optimal duration is not very clearly defined, but it is estimated as optimal 30 min sessions for 3 months, and the favorable effect can last up to 1 year. Repeated treatments may be required for sustained efficacy. Local discomfort is minimal and no serious side effects have been reported, being especially local and temporary (local inflammation, mild bleeding, pain) (1,13,14,18,67,69). PTNS contraindications are patients with implantable defibrillators, pacemakers, and nerve damage that can affect tibial nerve, bleeding problems, pregnancy or attempts to conceive (15). PTNS was approved by the US Food and Drug Administration (FDA) in 2005. There is also a possibility of a T-PTNS (transcutaneous stimulation) being performed (15).

Sacral neuromodulation (SNM) is recommended in selected severe cases that are refractory to other types of treatment and should be considered before resorting to other more radical ways of treatment (1,6,14,18). SNM consists of S3 nerve root stimulation using a percutaneously implantable device under fluoroscopic control, which generates electrical impulses (continuous low frequency stimulation is used to modulate bladder/pelvic floor function). The major disadvantage surgery is necessary to permanently implant a device, accompanied by related complications (pain, bleeding, infection, movement of the device or its malfunction) sometimes requiring reinterventions to revise the device (approximately 33% of cases). The final surgery occurs only after the patient's qualification for this procedure. A preliminary phase is necessary to determine whether or not the patient has a significant improvement in
symptoms (50% improvement in baseline symptoms). Only such patients may benefit from a full implant (1,13-15,18,70).

The advantages are important: the symptoms are significantly improved in over 50% of patients, with marked improvement in quality of life, the favorable effect being maintained up to 3-5 years (1,13,15,18,71,72). SNM is contraindicated in patients who need frequent MRI, pregnancy or if a patient aims to conceive. The device is not cost-effective, and the patient must be very compliant because lifelong follow-up is needed (14,15,73). Sacral neuromodulation was FDA approved in 1997.

**Augmentation cystoplasty and urinary diversion (fourth-line therapy).** In rare severe cases, refractory to any other type of treatment, surgical treatment can be performed; a form of fourth-line therapy (6,14). It is addressed to only selected cases. Patients must be very well informed about the consequences of interventions and should be very motivated. These forms of treatment are irreversible with a significant morbidity (13,14,18).

Augmentation of the bladder (cystoplasty) is performed by adding to its intraluminal surface area a 10-15 cm loop of small bowel, preferably ileum (detubularized segment of bowel is inserted into the bivalved bladder wall). The complications of the intervention can be redoubtable, with obstructions, disinsertions of anastomoses, abscesses, or fistulas (1,13,74).

Urinary diversion is an intervention that involves implanting the ureters in an ileal segment and creating a skin stoma (13,14,18).

The long-term complications of these types of surgery are electrolyte disturbances, renal failure, urinary tract stones, ischemia of the ileum and ureteric stricture, a need for clean intermittent self-catheterization (for bladder augmentation), change in bowel symptoms, or UTI (13,14,18). Patient satisfaction after such interventions is quite high, especially due to the fact that, having to resort to surgical treatment, they faced severe symptoms, refractory to any other type of treatment (13,14,18).

**Other possible treatments.** Other possible treatments for OAB are currently under investigation: α-adrenoceptor antagonists, gene therapy, neurokinin receptor antagonists, nerve growth factor inhibitors, stem cell-based therapies, potassium channel opening gates, capsaicin (resiniferatoxin), vaginal estrogen as a monotherapy for OAB as well as in combination with other therapies (including behavioral and pharmaceutical) (1,6,14,75-78).

6. **Discussion of the treatment algorithm**

OAB is a chronic, disabling condition, which requires a correct and sincere understanding of the problems it raises. The patient requires an explanation as clear as possible and the full support of the attending physician. Such a condition can be a considerable challenge for healthcare professionals, with a complete cure of OAB being almost impossible.

Often a multidisciplinary team is needed for a correct and complete approach to the case. In the vast majority of cases no additional investigations are necessary to establish the diagnosis. In most of the cases medical history and simple investigations are sufficient. Urodynamic tests or other investigations are necessary only in refractory to treatment cases.

It is advisable to utilize the 3-day micturition calendar, which has both the role of additional knowledge of the problem and the basis for subsequent reassessments. The use of quality of life questionnaires bring a great value in terms of scaling the degree of suffering (6,14,15,18,79,80).

The treatment must always be carried out gradually, starting with first-line treatment (behavioral therapy), lifestyle changes and bladder training. These have a low-risk profile (6,14,15,18). If no improvement is found in the patient's re-evaluation, the second-line treatment should be considered (pharmacological treatment)-anticholinergic medication or β3-agonists. At this stage the age, safety profile and history of the patient should be considered in order to select the optimal medication with maximum benefits and least side effects. The patient should also be informed of possible side effects and adjusting the doses accordingly upon re-evaluation (1-3 months) or at any time during treatment. The association between the two types of medication is allowed and even recommended in certain situations. In the vast majority of cases, the combination of first-line and second-line treatment produces excellent results (1,6,14,15,18,40,78-80).

If there is no improvement in any reassessment of the patient or if side effects are not tolerated (even if anticholinergic medication has been replaced or combination therapy has been used), the patient should be offered third-line therapy: temporary chemical denervation of the bladder detrusor muscle (intravesical botulinum toxin A), peripheral tibial nerve stimulation (PTNS) or neuromodulation. Patients must understand very clearly the favorable effects and the side effects of these types of treatment in order to make an informed decision (1,6,14,15,18).

In exceptionally rare cases, refractory to any type of exposed treatment, with marked impairment of quality of life, counseling is required in order to resort to fourth-line therapy: augmentation cystoplasty or urinary diversion. Patients must be very well informed about the consequences of the interventions, these interventions being irreversible and with significant morbidity (13-15,18).

7. **Conclusions**

OAB is a chronic, very disabling condition with physical, psychological and social consequences that significantly affect the quality of life of millions of patients worldwide. It is a little known condition, with different manifestations from patient to patient, which causes a lot of frustration to the medical staff involved. It is extremely important to establish a correct diagnosis and a treatment as efficient as possible, often individualized. The collaboration and understanding of these patients is an extremely important aspect. There are several treatment modalities that should be used progressively, with favorable but inconsistent results, which have been described in this study. Other types of treatment are being studied, with promising results. In the case of OAB, the patient's involvement must be optimal, so that the treatment options are clearly understood; the advantages and disadvantages of each, to make a correct and informed decision. Improving the quality of life in these patients is the main goal in managing this condition.
Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

IS, SL, OGB, AT, LSM and CCS, collected, analysed and interpreted the literature data. IS, SL, OGB, AT, LSM, AB, AGL, RMR, AML and CCS made substantial contributions to the conception of the work and interpretation of data; also, they drafted the manuscript and were major contributors in writing the manuscript. IS, SL, AT, CCS contributed equally to this study and should be regarded as co-first authors. All the authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript to be published, and are responsible for confirming the authenticity of the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Leron E, WeintraubAY, Mastrolia SA and Schwarzman P: Overactive bladder syndrome: Evaluation and management. Curr Urol 11: 117-125, 2018.
2. Abrams P, Kelleher CJ, Kerr LA and Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care 6 (Suppl): S580-S590, 2000.
3. Milson I, Abrams P, Cardozo L, Roberts RG, Thirstrup J and Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766, 2001.
4. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milson I and Chapple C: The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: Results from EpiliUTS. BJU Int 108: 1459-1471, 2011.
5. Donaldson MM, Thompson JR, Matthews RJ, Dalloz HM and McGrother CW; Leicestershire MRC Incontinence Study Group: The natural history of overactive bladder and stress urinary incontinence in older women in the community: A 3-year prospective cohort study. Neurourol Urodyn 25: 709-716, 2006.
6. Lightner DJ, Gomelsky A, Souter L and Vasavada SP: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline amendment 2019. J Urol 202: 558-563, 2019.
7. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL and Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol 20: 327-336, 2003.
8. Abrams P, Blair AS, Stamer SL and Anderson JT: The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl 114: 5-19, 1988.
9. Drake MJ: Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn 33: 623-624, 2014.
10. Van Den MM, Wijmstra H, Debruyne FM, De La Rosette JJ and Michel MC: The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 105: 1141-1146, 2010.
11. Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R and Finazzi-Agro E: Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int 89: 1-8, 2012.
12. Robinson D and Cardozo L: Managing overactive bladder. Climacteric 22: 250-256, 2019.
13. Burkhard FC, Bosch J, HR, Cruz F, Lemack GE, Nambiar AK, Thruchelvam N, Tabaro A, Ambühl D, Bedretinova DA, Farag E et al: Urinary Incontinence in Adults. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2020. https://uroweb.org/guideline/urinary-incontinence/. Access date: March 21, 2021.
14. Abbohud H, Fynes MM and Dauvourotchis SK: Contemporary therapy for the overactive bladder. Obstet Gynecol 135: 98-106, 2011.
15. Willis-Gray MG, Dieter AA and Geller EJ: Evaluation and management of overactive bladder: Strategies for optimizing care. Res Rep Urol 8: 113-122, 2016.
16. Milson I, Kaplan-Schmidt R, Sexton CC, Kopp CC and Kopp ZS: Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: Results from EpiliUTS. Urology 80: 90-96, 2012.
17. Irwin DE, Munapen L, Milson I, Kopp Z, Reeves P and Kelleher C: The economic impact of overactive bladder syndrome in six Western countries. BJU Int 103: 202-209, 2009.
18. Osman NI and Chapple CR: The management of overactive bladder syndrome: A review of the European Association of Urology Guidelines. Clin Pract 10: 593-606, 2013.
19. Hu TW and Wagner TH: Health-related consequences of overactive bladder: An economic perspective. BJU Int 96 (Suppl 1): S43-S45, 2005.
20. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE and Wagner TH: Impact of overactive bladder on work productivity in the United States: Results from EpiliUTS. Am J Manag Care 15 (Suppl 4): S98-S107, 2009.
21. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V and Mullins CD: The total economic burden of overactive bladder in the United States: A disease-specific approach. Am J Manag Care 15 (Suppl 4): 590-S97, 2009.
22. Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowsk R, Amarenco G, Gamé X, Kirby R, Van Der Aa F and Cornu JN: A comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment. Eur Urol 75: 1008-1000, 2019.
23. Robinson D, Cardozo L, Milson I, Pons ME, Kirby M, Koelbl H and Vierhout M: Oestrogens and overactive bladder. Neurourol Urodyn 33: 1086-1091, 2014.
24. de Boer TA, Salvatore S, Cardozo L, Chapple C, Kelleher C, van Kerrebroeck P, Kirby MG, Koelbl H, Espuna-Pons M, Milson I, et al: Pelvic organ prolapse and overactive bladder. Neurourol Urodyn 29: 30-39, 2010.
25. Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, Cruz F, Haab F, Kelleher C, Milson I, et al: Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract 69: 190-217, 2015.
26. de Boer TA, Slieker-ten Hove MC, Burger CW and Vierhout ME: The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J 22: 569-575, 2011.
27. Vrijens D, Drossaerts J, van Koeveringe G, van Kerrebroeck P, van Os J and Leue C: Affective symptoms and the overactive bladder-a systematic review. J Psychosom Res 78: 95-108, 2015.
28. Matsumoto S, Hashizume K, Wada N, Hori J, Tamagaki G, Kita M, Iwata T and Kizaki H: Relationship between overactive bladder and irritable bowel syndrome: A large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int 111: 647-652, 2013.
29. Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CL and Quentin Clemens J: The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by gender and race: Results from OAB-POLL. Neurourol Urodyn 32: 230-237, 2013.

30. Gleason JL, Richter HE, Redden DT, Goode PS, Burgio KL and Markland AD: Caffeine and urinary incontinence in US women. Int Urogynecol J 24: 295-302, 2013.

31. Abrams P, Cardozo L, Fall M, Gravas S and Madersbacher S: International Continence Society (ICS) Standardisation Sub-committee: The standardisation of terminology of lower urinary tract function: Report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178, 2002.

32. Wein AJ and Rackley RR: Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol 175: S5-S10, 2006.

33. Foon R and Toozh-Hobson P: Detrusor overactivity. Obstetrics, Gynaecol Reprod Med 17: 255-260, 2007.

34. Brading AF: Spontaneous activity of lower urinary tract smooth muscles: Correlation between ion channels and tissue function. J Physiol 570: 13-22, 2006.

35. Chapple C: Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of ‘overactive bladder’. Neurourol Urodyn (Suppl 4): S3-S13, 2013.

36. Lee SR, Kim HJ, Kim A and Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology 75: 1053-1059, 2010.

37. Hubeaux K, Deffieux X, Desseaux K, Verollet D, Damphousse M and Amarenco G: Stand up urgency: Is this symptom related to a urethral mechanism? Prog Urol 22: 475-481, 2012.

38. Apostolidis A, Wagg A, Rahnam Ai MS, Panicker JN, Vrijens D and von Gontard A: Is there ‘brain OAB’ and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017. Neurourol Urodyn 37 (Suppl 4): S38-S45, 2018.

39. Faraj K, Doo F, Boura J, Vereecke A and Chancellor MB: A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. Int Urol Nephrol 48: 197-1902, 2016.

40. Malone-Lee JG and Al-Buheissi S: Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 103: 931-937, 2009.

41. Inamura M, Williams K, Wells M and McGrother C: Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev 2: CD003505, 2015.

42. Kincaide JE, Dougherty MC, Carlson JR, Hunter GS and Robinson D and Cardozo L: Antimuscarinic drugs to treat overactive bladder: A systematic literature review and mixed treatment comparison. Eur Urol 65: 755-765, 2014.

43. Ostaszkiewicz J, Johnston L and Roe B: Timed voiding for treating overactive bladder. Br J Pharmacol 148: 565-578, 2009.

44. Robinson D and Cardozo L: Antimuscarinic drugs to treat overactive bladder. BMJ 344: e2130, 2012.

45. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X and Haag-Molkenteller C: EMBARK Study Group: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol 189: 2186-2193, 2013.

46. Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F and Kane RL: Benefits and harms of pharmacologic treatment for urinary incontinence in women: A systematic review. Ann Intern Med 156: 861-874, W3-1, 2012.

47. Kincade JE, Dougherty MC, Carlson JR, Hunter GS and Ulmsten U, van Kervel JW, Mutton A and Wein A: Standardisation Sub-committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: Report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178, 2002.

48. Lee SR, Kim HJ, Kim A and Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology 75: 1053-1059, 2010.

49. Khullar V, Amarenco G, Angulo JC, Cambroner J, Høye K, Milsom I, Radziszewski P, Recherberger T, Boertriger P, Drogenidj T, et al: Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder. Results from a randomised European-Australian phase 3 trial. Eur Urol 63: 283-295, 2013.

50. Maman K, Abullea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I and Hakimi Z: Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. Eur Urol 65: 755-765, 2014.

51. Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T and Chapple CR: Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol 9: 311-323, 2016.

52. Wagg A, Franks B, Ramos B and Berner T: Persistence and adherence with the new β3 adrenoceptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J 19: 343-350, 2015.

53. Abrams P, Kelleher C, Staskin D, Recherberger T, Kay R, Martin A, Newgreen D, Paireddy A, van Maanen R and Ridder A: Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67: 577-585, 2015.

54. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Graves S and Madersbacher S: Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botulinum toxin (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60: 784-795, 2011.

55. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J and Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184: 2416-2422, 2010.

56. Apostolidis A, Dasgupta P, Denys P, Elinei S, Fowler CJ, Giannantoni A, Karsegyt G, Schulte-Baukloh H, Schurch B and Wyndaele JJ: European Consensus Panel: Recommendations on the use of botulinum toxin type A for the treatment of urinary incontinence disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol 55: 100-119, 2009.

57. Mascarenhas F, Coccuzza M, Gomes CM and Leão N: Trigonal injection of botulinum toxin-A does not cause vesicourethral reflux in neurogenic patients. Neurouroul Urodyn 27: 311-314, 2008.

58. Dowson C, Watkins J, Khan MS, Dasgupta P and Sahai A: Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and cost-effectiveness. J Continuum Ther 20: W301-W307, 2012.

59. Ridout AE and Yoong W: Tibial nerve stimulation for overactive bladder syndrome. BMJ 344: e2130, 2012.

60. Peeker R, Samsioe G, Kowalski J, Andersson AS and Bergqvist A: Tibial nerve stimulation for overactive bladder: A systematic review of the literature. Int J Clin Pract 65: 876-875, 2011.

61. Robinson D and Cardozo L: Antimuscarinic drugs to treat overactive bladder. BMJ 344: e2130, 2012.

62. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J and Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184: 2416-2422, 2010.
68. Govier FE, Litwiller S, Nitti V, Kreder KJ Jr and Rosenblatt P: Percutaneous afferent neuromodulation for the refractory overactive bladder: Results of a multicenter study. J Urol 165: 1193-1198, 2001.
69. MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, Siegel SW, Tate SB and Feagins BA: Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 183: 234-240, 2010.
70. Price N, Dawood R and Jackson SR: Pelvic floor exercise for urinary incontinence: A systematic literature review. Maturitas 67: 309-315, 2010.
71. Janknegt RA, Hassouna MM, Siegel SW, Schmidt RA, Gajewski JB, Rivas DA, Elhilali MM, Milam DC, van Kerrebroeck PE, Dijkema HE, et al: Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol 39: 101-106, 2001.
72. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, et al: Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J Urol 178: 2029-2034, 2007.
73. Pathak AS and Aboseif SR: Overactive bladder: Drug therapy versus nerve stimulation. Nat Clin Pract Urol 2: 310-311, 2005.
74. Somani BK, Kumar V, Wong S, Pickard R, Ramsay C, Nabi G, Grant A and NDow J; ABACUS Research Group: Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. J Urol 177: 1793-1798, 2007.
75. Epstein BJ, Gums JG and Molina E: Newer agents for the management of overactive bladder. Am Fam Physician 74: 2061-2068, 2006.
76. Silva C, Silva J, Ribeiro MJ, Avelino A and Cruz F: Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: Results of a double-blind randomized placebo-controlled trial. Eur Urol 48: 650-655, 2005.
77. Lewis JM and Cheng EY: Non-traditional management of the neurogenic bladder: Tissue engineering and neuromodulation. ScientificWorldJournal 7: 1230-1241, 2007.
78. Chancellor MB and Hasenau DL: Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder? Rev Urol 10: 306-308, 2008.
79. Dan Spinu A, Gabriel Bratu O, Cristina Diaconu C, Maria Alexandra Stanescu A, Bungau S, Fratila O, Bohiltea R and Liviu Dorel Mischianu D: Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). Exp Ther Med 20: 117-120, 2020.
80. Scarneciu I, Bungau S, Lupu AM, Scarneciu CC, Bratu OG, Martha O, Tit DM, Aleya L and Lupu S: Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections-Long-term results of a multicenter study. Eur J Pharm Sci 139: 105067, 2019.